The number of people dying from breast, prostate and bowel cancer will almost halve in the three decades up to 2020, new figures suggest.
Just over a third - 36 per cent - of breast cancer patients will ultimately die from their disease, down from 61 per cent in 1992.
Some 36 per cent of prostate cancer patients will also die, according to projections for 2020, down from 72 per cent in 1992.
And almost two in five (39 per cent) people with bowel cancer will die from their disease, down from 67 per cent in 1992.
The data, from Macmillan Cancer Support, shows lung cancer lagging behind, with 76 per cent of patients expected to die from their disease, compared with 91 per cent in 1992.
Survival from lung cancer has been historically low, with experts suggesting a range of reasons, including people going to their GP too late with symptoms and unequal access to surgery depending on where people live.
Previous Macmillan research estimated that by 2020 almost half (47 per cent) of people will get cancer in their lifetime and 38 per cent would survive the disease.
The new data suggests there is a difference in survival expectations depending on the type of cancer.
Professor Jane Maher, chief medical officer of Macmillan Cancer Support, said: “People diagnosed with three of the four most common cancers are more likely to survive but GPs need more support to help them diagnose lung cancer earlier.
“We’ve been working with the GP community to develop the tools that can help.”
Ciarán Devane, chief executive of Macmillan Cancer Support, said: “Lung cancer patients deserve better. It is high time we closed the gap between survival rates for different cancers and give everyone the best possible chance of recovery.
“There are three key things that could help to achieve this.
“Firstly, we support the call for plain packaging of cigarettes to stop people taking up smoking, secondly we must catch the illness earlier through better awareness and we have to make sure access to surgery is more uniform across the country to reduce inequalities in cancer survival.
“It cannot be right that you are much more likely to get the surgery you need if you live in Leicestershire than if you live in Lancashire.”